Monday 20 August 2012

Prevention of Calcitriol


Welcome To Plenus Pharmaceuticals (P) Ltd 
Plenus Pharmaceuticals is built on its meaning of completeness in pharmaceutical field through our quality healthcare service that leads to healthy life everywhere. It is complete healthcare in every aspect where there is no compromise with quality of products, ensuring full satisfaction to concerned entities.

Prevention of secondary hyperparathyroidism with either oral or intravenous administration of calcitriol has been recommended for dialysis patients. The use of calcitriol among patients with chronic kidney disease has been suggested, though evidence for its use is limited. The demonstrated benefits of predialysis calcitriol administration include a decrease in serum parathyroid levels.The primary risk of calcitriol administration is an elevated serum calcium level. Concern exists regarding the development of adynamic bone disease, which occurs with overzealous suppression of parathyroid hormone. A potential benefit of predialysis calcitriol administration is decreased secondary hyperparathyroidism after institution of hem dialysis.

Monitoring bone disease and secondary hyperparathyroidism may be considered less of a priority than other issues during the period leading up to dialysis. Oversight of bone disease management with the use of a protocol to monitor serum calcium, phosphorous, and iPTH levels may be a means for avoiding this problem. Dietitians familiar with bone disease issues, patient education, and calcitriol use seem an appropriate group to help in this endeavor.


Keywords


Contact Us-

Plenus Pharmaceuticals Private Limited
PLENUS BUILDING
SHIV VIHAR, NEAR LAL MANDIR,
ARYA NAGAR JWALAPUR,
HARIDWAR. (U.K.) 249407
Mobile: 09737475726













Thursday 9 August 2012

Effects of a Calcitriol


Welcome To Plenus Pharmaceuticals (P) Ltd 
 Plenus Pharmaceuticals is built on its meaning of completeness in pharmaceutical field through our quality healthcare service that leads to healthy life everywhere. It is complete healthcare in every aspect where there is no compromise with quality of products, ensuring full satisfaction to concerned entities.

A calcitriol administration protocol was used with patients beginning on June 1, 2001. Mean serum intact parathyroid hormone , calcium, and phosphorous levels from the three months preceding and three months following initiation of dialysis were measured. A significant difference in iPTH levels between patients treated under the calcitriol protocol and patients in the control group was observed. Patients with end-stage renal disease frequently develop secondary hyperparathyroidism because of decreased production of 1,25(OH)2-vitamin D (calcitriol) in the kidneys. The onset of secondary hyperparathyroidism occurs early in chronic renal failure. Patients with glomerular filtration rates (GFRs) as high as 60 mL/min/1.73 m2 may begin to produce decreased levels of calcitriol, resulting in increased intact parathyroid hormone  and increased serum phosphorous levels.


Keywords


Contact Us-

Plenus Pharmaceuticals Private Limited
PLENUS BUILDING
SHIV VIHAR, NEAR LAL MANDIR,
ARYA NAGAR JWALAPUR,
HARIDWAR. (U.K.) 249407
Mobile: 09737475726